Reviva Pharmaceuticals Files 2024 10-K
Ticker: RVPH · Form: 10-K · Filed: Apr 3, 2025
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Reviva Pharma 2024 10-K: $118M assets, $111M liabilities, $4.6M revenue, $3.4M loss. Still in pharma prep.
AI Summary
Reviva Pharmaceuticals Holdings, Inc. filed its 2024 10-K on April 3, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Tenzing Acquisition Corp., is focused on pharmaceutical preparations. Key financial figures include total assets of $118 million and total liabilities of $111 million for the fiscal year 2024. The company also reported net revenue of $4.6 million and a net loss of $3.4 million.
Why It Matters
This filing provides a comprehensive overview of Reviva Pharmaceuticals' financial health and operational status for the fiscal year 2024, crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company reported a net loss, indicating ongoing financial challenges typical for pharmaceutical development companies, which warrants a medium risk assessment.
Key Numbers
- $118M — Total Assets (As of December 31, 2024)
- $111M — Total Liabilities (As of December 31, 2024)
- $4.6M — Net Revenue (For the fiscal year ended December 31, 2024)
- $3.4M — Net Loss (For the fiscal year ended December 31, 2024)
- 2024-12-31 — Fiscal Year End (Reporting period)
Key Players & Entities
- REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Filer
- Tenzing Acquisition Corp. (company) — Former company name
- 2024-12-31 (date) — Fiscal year end
- 20250403 (date) — Filing date
- $118 million (dollar_amount) — Total assets for FY 2024
- $111 million (dollar_amount) — Total liabilities for FY 2024
- $4.6 million (dollar_amount) — Net revenue for FY 2024
- $3.4 million (dollar_amount) — Net loss for FY 2024
FAQ
What was Reviva Pharmaceuticals' net revenue for the fiscal year ended December 31, 2024?
Reviva Pharmaceuticals reported net revenue of $4.6 million for the fiscal year ended December 31, 2024.
What was the company's net loss for the fiscal year ended December 31, 2024?
The company reported a net loss of $3.4 million for the fiscal year ended December 31, 2024.
What were the total assets and total liabilities of Reviva Pharmaceuticals as of December 31, 2024?
As of December 31, 2024, Reviva Pharmaceuticals had total assets of $118 million and total liabilities of $111 million.
When was Reviva Pharmaceuticals Holdings, Inc. formerly known as?
Reviva Pharmaceuticals Holdings, Inc. was formerly known as Tenzing Acquisition Corp., with a name change date of June 6, 2018.
What is Reviva Pharmaceuticals' primary industry classification?
Reviva Pharmaceuticals Holdings, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 3, 2025 regarding REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).